The aim of the present study is to biomonitor the tolerance level of roadside plant species towards mitigation of air pollution for the development of greenbelt. The leaves of four plant species (Azadirachta indica, Ficus benghalensis, Melia azedarach and Polyalthia longifolia) were collected from 41 sampling sites of Bathinda city during summer and winter seasons.  https://www.selleckchem.com/products/cp2-so4.html  Seasonal variation in APTI and API was determined in selected plants. Highest APTI (13.54) was reported in F. benghalensis during summer and lowest APTI (11.69) in A. indica during winter season. The APTI and API value revealed that F. benghalensis was the best performer, A. indica and M. azedarach were excellent performers and P. longifolia a good performer in greenbelt development to mitigate the air pollution. Pearson's correlation analysis illustrated significant correlation between APTI, ascorbic acid, total chlorophyll, relative water and pH, respectively.Background The prognosis of esophageal squamous cell carcinoma (ESCC) are still poor. Nedaplatin/paclitaxel regimen has shown activity with lower toxicity in metastatic ESCC. Recombinant human endostatin (Rh-endostatin), an inhibitor of angiogenesis, has shown inhibitory effects on ESCC xenograft. We assessed the activity and safety of Rh-endostatin plus paclitaxel/nedaplatin in patients with recurrent or metastatic advanced ESCC. Methods In this single-center, open-label, single-arm, phase II study, patients with recurrent/metastatic or unresectable advanced ESCC were recruited. Eligible patients received the multidrug combination therapy with Rh-endostatin (30 mg/day on days 1-14), paclitaxel (150 mg/m2 on day 4) and nedaplatin (80 mg/m2 on day 4) every 3 weeks. The primary endpoint was progression-free survival. Secondary endpoints included objective response rate, disease control rate, overall survival. Results Between Jan 29, 2015 and Dec 31, 2019, 53 patients were enrolled and received at least one dose of Rh-endostatin. Median progression-free survival was 5.1 months (95% CI 3.7-6.6), with a 6 month progression-free survival of 41% (95% CI 25-56). Median overall survival was 13.2 months (95% CI 8.0-18.4), with a 1-year overall survival of 51% (95% CI 36-67). 21 (42%, 95% CI 28-56) of 50 patients had an objective response and 35 (70.00%, 95% CI 57-83) had a disease control. Treatment-related adverse events of grade 3 or worse were reported in 13 (24.5%) patients. The most common grade 3 or 4 treatment-related adverse events were neutropenia (9 patients [17%]) and anaemia (2 [3.8%]). No treatment-related death occurred. Conclusions Rh-endostatin plus paclitaxel/nedaplatin has anti-tumour activity with acceptable tolerability in patients with recurrent or metastatic advanced ESCC. Randomized controlled trial is needed to confirm the efficacy of this regimen.
  Peripheral T cell lymphomas (PTCLs) have an overall poor prognosis. Indeed, registry data in elderly patients show that the median progression-free survival (mPFS) following first- and second-line therapies are only 6.7 and 3.1months, respectively. The aim of the study is to show the activity of metronomic chemotherapy, a regular administration of low chemotherapeutic drug doses allowing a favourable toxicity profile, on elderly PTCL patients.
 
  We report a series of 17 PTCL patients, treated with the all-oral metronomic schedule DEVEC (prednisolone-etoposide-vinorelbine-cyclophosphamide) in four Italian centres. Patients 5/17 (29.4%) were treatment-naïve (naïve) and 12/17 (70.6%) were relapsed-refractory (RR), respectively. The median age was 83years (range 71-87) and 71.5years (range 56-85) for naïve and RR, respectively. In vitro activity of metronomic vinorelbine (VNR), etoposide (ETO) and their concomitant combination on HH, a PTCL cell line, was also assessed.
 
  Histology PTCL-not-otherwise-specified = 12; angioimmunoblastic = 2; NK/T nasal type = 1; adult-type leukaemia lymphoma = 1, transformed Mycosis Fungoides = 1. The overall response rate was 80 and 58% in naïve and RR, respectively; whereas the PFS was 20 in naïve (95% CI 0-43) and 11months (95% CI 4.2-17.8) in RR. The occurrence of relevant adverse events was 23.5%, which was managed with ETO dose reduction. In vitro experiments showed that both metronomic VNR and ETO caused a significant inhibitory activity on HH cells and a strong synergism when administered concomitantly.
 
  All-oral DEVEC showed an encouraging activity and acceptable toxicity. This schedule deserves further studies in elderly PTCL also for assessing combinations with targeted drugs.
 All-oral DEVEC showed an encouraging activity and acceptable toxicity. This schedule deserves further studies in elderly PTCL also for assessing combinations with targeted drugs.The analysis of movements used in physiotherapy areas related to the elderly is becoming increasingly important due to factors such as the increase in the average life expectancy and the rate of elderly people over the whole population. In this systematic review, we try to determine how the inertial sensors embedded in mobile devices are exploited for the measurement of the different parameters involved in the Timed-Up and Go test. The results show the mobile devices equipped with onboard motion sensors can be exploited for these types of studies the most commonly used sensors are the magnetometer, accelerometer and gyroscope available in consumer off-the-shelf smartphones. Other features typically used to evaluate the Timed-Up and Go test are the time duration, the angular velocity and the number of steps, allowing for the recognition of some diseases as well as the measurement of the subject's performance during the test execution.APEGylatedcurcumin (PCU) loaded electrospuns based on poly(ε-caprolactone) (PCL) andpolyvinyl alcohol (PVA) were fabricated for wound dressing applications. The main reason for this wound dressing design is antibacterialactivity enhancement, and wound exudates management. PEGylation increases curcuminsantibacterial properties and PVA can help exudates management. For optimal wound dressing, first, response surface methodology (RSM) was applied to optimize the electrospinning parameters to achieve appropriate nanofibrous mats. Then a three-layer electrospun was designed by considering the water absorbability, PCU release profile as well as antibacterial and biocompatibility of the final wound dressing. The burst release in controlled release systems could be evaluated for prevention of the higher initial drug release and control the effective life time. The PCU release results illustrated that the bead knot plays a positive role in controlling the release profile andby increase in the number of beads per unit area from 3000 to 9000 mm-2,the PCU burst release will be reduced; Also in vitro studies show that optimized three-layer dressing based on PCL/PVA/PCU can support water vapour transmission rate in optimal range and also absorb more than three times exudates in comparison with mono-layerdressing.